Distinct Profiles of Consumers of Psychoactive Substances in People Attending French Sexual Transmitted Infections Centers

  • H. PeyrièreEmail author
  • Q. Mano
  • V. Tribout
  • J. M. Jacquet
  • M. Ferreira
  • E. De Carvalho
  • I. Brosson
  • J. Verdier
  • J. Derrien
  • C. Rousseau
  • J. Reynes
  • the Study Group of Investigators
Original Paper


The objective of this cross-sectional survey was to assess the prevalence of psychoactive substance use (PSU) in people attending 11 French Sexual Transmitted Infection Centers, and to specify their profiles (PSU and link with risky sexual behaviors) using the ascending hierarchical clustering method. Among the 5220 individuals who completed the survey, 55.6% were men and the median age was 24 years [IQR: 20–31]. Among the participants, 2751 (52.7%) reported PSU at least once in their life. Ascending hierarchical clustering identified seven distinct profiles of participants based on their PSU. This study shows a high prevalence of PSU and alcohol consumption in this young population. Moreover, subgroup analysis allowed identifying groups of psychoactive substance users who presented specific risks or vulnerabilities and who should be priority targets for interventions, particularly sexual minority groups.


Psychoactive substance Ascending hierarchical classification Profile Sexual transmitted infections centers 


El objetivo de esta encuesta trasversal era evaluar, en individuos que consultaron 11 centros franceses de Enfermedades de Trasmisión Sexual, la prevalencia del uso de sustancias psicoactivas y precisar el perfil de los participantes (sustancias psicoactivas y su relación con comportamientos de riesgo sexual) utilizando el método de clasificación jerárquica ascendente. Entre los 5220 individuos que completaron la encuesta, 55.6% eran hombres con una edad media de 24 años [IQR: 20–31]. Entre los participantes, 2751 (52.7%) declararon el uso de sustancias psicoactivas al menos una vez en su vida. El método de clasificación jerárquica ascendente identificó siete perfiles diferentes de participantes en base a su uso de sustancias psicoactivas. Esta encuesta muestra una elevada prevalencia del consumo de sustancias psicoactivas y alcohol en este grupo de población joven. Más aún, el análisis de subgrupos permite identificar grupos de consumidores de sustancias psicoactivas que presentan riesgos o vulnerabilidades específicas, a quienes deberían proponerse intervenciones con prioridad, particularmente a los grupos de minorías sexuales.



Study conception and coordination: CR; protocol drafting: CR, JR, HP, VT, JMJ, MF, EDC, IB, JV, JD; data acquisition: VT, MF, EDC, IB, JV; data analysis: QM, CR; drafting of first manuscript: HP; revision of manuscript: HP, JR, CR, QM; final approval of manuscript: all authors.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Informed Consent

Informed consent was obtained from all participants included in the study.

Supplementary material

10461_2019_2539_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 18 kb)


  1. 1.
    Bouvet E, Le Vu S. Free anonymous screening consultation and clinical management of HIV infection. Med Sci MS. 2004;20(12):1145–8.Google Scholar
  2. 2.
    Le Vu S, Semaille C. Free and anonymous HIV testing in France, 2006. Bull Epidemiol Hebd. 2008;7–8:49–52.Google Scholar
  3. 3.
    Inpes, Atlas des usages de substances psychoactives 2010 - Indicateurs. 2013.
  4. 4.
    Surveillance du VIH/sida en France. Données au 30 juin 2011.
  5. 5.
    Velter A, Sauvage C, Saboni L, et al. 2017. Estimation de la prévalence du VIH chez les hommes ayant des relations sexuelles avec des hommes frequentant les lieux de convivialité gay de cinq villes françaises—PREVAGAY 2015. Bull Epidémiol Hebd. 18:347-54.
  6. 6.
    Melendez-Torres GJ, Hickson F, Reid D, Weatherburn P, Bonell C. Nested event-level case-control study of drug use and sexual outcomes in multipartner encounters reported by men who have sex with men. AIDS Behav. 2016;20(3):646–54.CrossRefGoogle Scholar
  7. 7.
    Brunault P, Bray A, Rerolle C, Cognet S, Gaillard P, El-Hage W. Differences in access to Internet and Internet-based information seeking according to the type of psychiatric disorder. Rev Epidemiol Sante Publique. 2017;65(2):125–36.CrossRefGoogle Scholar
  8. 8.
    Correll CU, Cañas F, Larmo I, et al. Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. Eur Psychiatry. 2011;26(Suppl 1):3–16.CrossRefGoogle Scholar
  9. 9.
  10. 10.
    Qannari EM, Vigneau E, Courcoux P. Une nouvelle distance entre variables. Application en classification. Revue de Statistique Appliquée. 1998;46(2):21–32.Google Scholar
  11. 11.
    Izenman AJ. Modern multivariate statistical techniques: regression, classification and manifold learning. Illustrated edn 2008 ed. New York: Springer; 2008. p. 407–420.Google Scholar
  12. 12.
    Chevallier C, Batisse A, Marillier M, Segouin C, Djezzar S. Profil des usagers de substances psychoactives consultant dans un centre gratuit d’information, de dépistage et de diagnostic (CEGIDD) à Paris. XVIIè congrès de la Société Française de Lutte contre le SIDA 6-7 octobre 2016, Montpellier, France, poster 13.Google Scholar
  13. 13.
    Laanani M, Dozol A, Meyer L, et al. Factors associated with failure to return for HIV test results in a free and anonymous screening centre. Int J STD AIDS. 2015;26(8):549–55.CrossRefGoogle Scholar
  14. 14.
    Beck F, Richard JB, Guignard R, Le Nézet O, Spilka S. Les niveaux d’usage des drogues en France en 2014. Tendance Mars, 2015; 99:12.
  15. 15.
    Green KE, Feinstein BA. Substance use in lesbian, gay, and bisexual populations: an update on empirical research and implications for treatment. Psychol Addict Behav. 2012;26(2):265–78.CrossRefGoogle Scholar
  16. 16.
    Mackesy-Amiti ME, Fendrich M, Johnson TP. Symptoms of substance dependence and risky sexual behavior in a probability sample of hiv negative men who have sex with men in chicago. Drug Alcohol Depend. 2010;110(1–2):38–43.CrossRefGoogle Scholar
  17. 17.
    Sewell J, Miltz A, Lampe FC, et al. For the Attitudes to and understanding of risk of acquisition of HIV (AURAH) study group poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics. Int J Drug Policy. 2017;43:33–43.CrossRefGoogle Scholar
  18. 18.
    Bourne A, Reid D, Hickson F, Torres-Rueda S, Weatherburn P. Illicit drug use in sexual settings (‘chemsex’) and HIV/STI transmission risk behaviour among gay men in South London: findings from a qualitative study. Sex Transm Infect. 2015;91(8):564–8.CrossRefGoogle Scholar
  19. 19.
    Cochran SD, Ackerman D, Mays VM, Ross MW. Prevalence of non-medical drug use and dependence among homosexually active men and women in the US population. Addiction. 2004;99(8):989–98.CrossRefGoogle Scholar
  20. 20.
    Parsons JT, Kelly BC, Wells BE. Differences in club drug use between heterosexual and lesbian/bisexual females. Addict Behav. 2006;31(12):2344–9.CrossRefGoogle Scholar
  21. 21.
    Knight DA, Jarrett D. Preventive health care for women who have sex with women. Am Fam Physician. 2017;95(5):314–21.Google Scholar
  22. 22.
    Ford JA, Jasinski JL. Sexual orientation and substance use among college students. Addict Behav. 2006;31(3):404–13.CrossRefGoogle Scholar
  23. 23.
    Prestage G, Hammoud M, Jin F, Degenhardt L, Bourne A, Maher L. Mental health, drug use and sexual risk behavior among gay and bisexual men. Int J Drug Policy. 2018;55:169–79.CrossRefGoogle Scholar
  24. 24.
    Matthews AK, Cho YI, Hughes T, Wilsnack SC, Johnson T, Martin K. The relationships of sexual identity, hazardous drinking, and drinking expectancies with risky sexual behaviors in a community sample of lesbian and bisexual women. J Am Psychiatr Nurses Assoc. 2013;19(5):259–70.CrossRefGoogle Scholar
  25. 25.
    Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefGoogle Scholar
  26. 26.
    World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO; 2015.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • H. Peyrière
    • 1
    • 9
    Email author
  • Q. Mano
    • 2
  • V. Tribout
    • 3
  • J. M. Jacquet
    • 4
  • M. Ferreira
    • 5
  • E. De Carvalho
    • 6
  • I. Brosson
    • 7
  • J. Verdier
    • 5
  • J. Derrien
    • 8
  • C. Rousseau
    • 2
  • J. Reynes
    • 1
    • 4
  • the Study Group of Investigators
  1. 1.INSERM U1175/IRD UMI 233, Montpellier UniversityMontpellierFrance
  2. 2.Santé Publique France, French National Public Health AgencySaint-MauriceFrance
  3. 3.Sexual Transmitted Infections CenterMontpellier UniversityMontpellierFrance
  4. 4.Department of Infectious DiseasesMontpellier University HospitalMontpellierFrance
  5. 5.Sexual Transmitted Infections CenterPerpignanFrance
  6. 6.AIDS Information ServiceNîmesFrance
  7. 7.Sexual Transmitted Infections CenterNîmesFrance
  8. 8.National Team of Intervention and Prevention in HealthMontpellierFrance
  9. 9.Département de Pharmacologie Médicale et ToxicologieHôpital LapeyronieCedex 5 MontpellierFrance

Personalised recommendations